Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

201197 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 12, Issue 3, pp. 263-272

Field-Weighted Citation Impact: 8.21